RedHill Biopharma Ondansetron Hydrochloride CR for Gastroenteritis: Likelihood of Approval

In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.

Ondansetron Hydrochloride CR Overview

Ondansetron hydrochloride (RHB-102, Bekinda) is being developed for the treatment of acute gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), and nausea and vomiting associated with chemotherapy and radiation therapy. The drug candidate is administered orally in tablet form. It is a proprietary formulation of 11 daily controlled-release ondansetron. The drug candidate is developed based on CDT (Controlled Delivery Technology) technology. It is a controlled release formulation.

RedHill Biopharmaceutical Overview

RedHill Biopharma (RedHill) is a specialty biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio includes branded prescription medicines, including omeprazole, a combination of amoxicillin and rifabutin; naloxitol; and rifamycins. RedHill is studying its use as a treatment for Crohn’s disease, non-tuberculous mycobacterial (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleansing, cancer and novel coronavirus Product candidates for COVID-19. ). The company has subsidiaries in the United States. RedHill is headquartered in Tel Aviv, Israel.

For complete information on drug-specific PTSR and LoA scores for Ondansetron Hydrochloride CR, purchase the report here.

This content was updated on September 10, 2023


The gold standard in business intelligence.

GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.

Global Data

GlobalData, a leading provider of industry intelligence, provided the underlying data, research and analysis used to write this article.

GlobalData’s Likelihood of Approval Analysis tool dynamically assesses and predicts the likelihood of a drug advancing to the next phase of clinical development (PTSR), as well as the likelihood of drug approval (LoA). This is based on a combination of machine learning and proprietary algorithms used to process data points from various databases in GlobalData’s Pharmaceutical Intelligence Center.

Source link

Leave a Comment